Prostate cancer (PCa) and benign prostatic hyperplasia (BPH), were investigated in both AL-Basra and Missan provinces–Iraq. The study provides data relating serum selenium (Se), arsenic(As), zinc(Zn), and copper(Cu) levels to activity ofGlutathione–S– transferase (GST), Malondialdehyde (MDA); and prostate specific antigen (PSA) . sixty patients (30 patientswith BPH mean age 56.40 ± 9.74 years and 30 patients with PCa mean age 57.55 ± 9.15 years) and thirty healthy controlsmean age (54.150 ± 7.856) years were participated in the study. The results revealed a highly significant difference (P<0.001)in MDA, PSA, and Se levels; significant different in GST, Zn, and Cu/Zn ratio levels. No statistical significant difference wasfound in mean age, As, Cu, and E2 in BPH as compared to control group. Also, there was no statistical significant differencein mean age, and E2 level in PCa patients when compared to control group, while there was a highly significant difference(p<0.001) in MDA, PSA, GST, Se, As, Zn, and Cu/Zn ratio levels; and significant difference in Cu and testosterone levels weredetected in PCa patients as compared to control group. Correlations studies indicated a significant correlation between MDAand ) PSA, GST, Se, As ,Zn ,Cu, Cu/Zn, Testosterone, and E2) in BPH and PCa patients. In conclusion, trace elements whichused in this study (Zn, As, Se, and Cu) can be used as a bioindicator for prostate illness. Serum MDA may be considered amarker for predicting prostate cancer as a compliment to PSA.
